Regeneron Pharmaceuticals

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: REGN-1 Category:

Description

Regeneron Pharmaceuticals, Inc. delivered an all-around beat in the previous quarter, witnessing a commendable 15% surge in total revenues. The notable upswing was propelled by increased Sanofi collaboration revenues and a remarkable 62% growth in LIBTAYO global net product sales, complemented by a 50% surge in Dupixent global net product sales, totaling $3.1 billion. In the quarter, the management highlighted the successful launch of EYLEA HD, which achieved $43 million in net product sales within the final six weeks of the quarter. EYLEA HD samples were swiftly made available post-launch, facilitating prescribers and patients to trial the product across various indications of wet age-related macular degeneration and diabetic macular edema. Regeneron’s pipeline progress was underscored, especially in hematology-oncology, with the FDA accepting the BLA for odronextamab and granting priority review. Progress on linvoseltamab for multiple myeloma was also highlighted, with pivotal trials underway for potential accelerated approvals and commercial launches anticipated next year. A breakthrough in gene therapy for profound congenital hearing loss was reported, showcasing positive results in the DB-OTO Phase I/II CHORD clinical trial. In conclusion, Regeneron’s third quarter was robust, marked by the successful EYLEA HD launch, pipeline advancements, and a strategic focus on capital allocation.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!